Skip to content

Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens

Clinical Validation of Etafilcon A With Print and PVP Contact Lenses for Dark Eyes and Light Eyes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01484028
Enrollment
275
Registered
2011-12-02
Start date
2011-11-30
Completion date
2012-02-29
Last updated
2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Ametropia

Brief summary

This study will serve to evaluate and compare the performance of two new lenses to a marketed lens.

Interventions

DEVICEetafilcon A control lens (1DM)

A marketed daily disposable contact lens

DEVICEetafilcon A with print and PVP for light eyes (EALE)

A daily disposable contact lens

DEVICEetafilcon A with print and PVP for dark eyes (EADE)

A daily disposable contact lens

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 34 Years
Healthy volunteers
No

Inclusion criteria

* Healthy, female adult, at least 18 years of age, and no more than 34 years of age * The subjects must be female, light eye Caucasian, Non-Hispanic, habitual soft contact lens wearer (both eyes) with light or dark eyes * Must have rated the Concept Statement positively (i.e., a rating of 4 or 5). * Optimal vertexed spherical equivalent distance correction must be between -1.00 and -4.00 diopters (D) * Any cylinder power must be: \<=0.75D * Visual acuity must be best correctable to 20/25 or better for each eye * Must have normal eyes (no ocular medications or ocular infection of any type) * Must read and sign the Statement of Informed Consent * Must appear able and willing to adhere to the instructions set forth in this clinical protocol.

Exclusion criteria

* Ocular or systemic allergies or disease which might interfere with contact lens wear * Systemic disease, autoimmune disease, or use of medication which might interfere with contact lens wear * Clinically significant (grade 3 or worse) corneal edema, corneal neovascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear * Clinically significant (grade 3 or 4) tarsal abnormalities or bulbar injection which might interfere with contact lens wear * Any ocular infection * Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear * Any color deficiencies (colorblindness) - to the best of the subject's knowledge * Pregnancy or lactation * Diabetes * Infectious diseases (e.g. hepatitis, tuberculosis) or an immuno-suppressive disease (e.g. HIV) * Habitual contact lens type is toric, multifocal, or is worn as extended wear. * Subject presents with one dark iris color and one light iris color. * Subject has heterochromia iridis (a difference in color between parts of one iris). * The subject must not be an employee or family member of the clinical study site.

Design outcomes

Primary

MeasureTime frameDescription
Monocular Visual AcuityDispensingMonocular distance Snellen visual acuity (VA) scores were coverted to the algorithm of the minimal angle of resolution (LogMAR) scale based on the following formula: LogMAR = Log10 (VA/20) - a\*VAR, where Log10 = base 10 logarithm, VA = the Snellen denominator score, a = LogMAR stepsize coefficient and VAR = letter gained or missing in addition to the Snellen denominator score.
Lens Fit AcceptanceDispensingThe overall lens fit was evaluated by the Investigators for each eye whether it was acceptable (yes/no).
Corneal Staining of Grade 3 or 4After 7-9 days of lens wearCorneal staining was graded using a 5-point scale; 0=None(no staining), 1=Trace, 2=Mild, 3=Moderate, and 4=Severe. Only those eyes with corneal staining grade \>= 3 were reported.

Countries

United States

Participant flow

Pre-assignment details

Of those 275 enrolled subjects, 267 subjects were randomized and received the study article in the study. Two subjects were discontinued between the first and second periods.

Participants by arm

ArmCount
All Subjects
All randomized subjects who worn at least one pair of study lenses.
267
Total267

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Period 1Lens Discomfort0100
Period 1Lost to Follow-up0100
Period 1Non-Compliance to Protocol0101

Baseline characteristics

CharacteristicAll Subjects
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
267 Participants
Age, Continuous24.94 years
STANDARD_DEVIATION 4.654
Sex: Female, Male
Female
267 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 2670 / 267
serious
Total, serious adverse events
0 / 2670 / 267

Outcome results

Primary

Corneal Staining of Grade 3 or 4

Corneal staining was graded using a 5-point scale; 0=None(no staining), 1=Trace, 2=Mild, 3=Moderate, and 4=Severe. Only those eyes with corneal staining grade \>= 3 were reported.

Time frame: After 7-9 days of lens wear

Population: Analysis was conducted on all randomized subjects who wore at least one pair of study lenses.

ArmMeasureValue (NUMBER)
EADE/EALECorneal Staining of Grade 3 or 40 % of Eyes
1-DMCorneal Staining of Grade 3 or 40 % of Eyes
Primary

Lens Fit Acceptance

The overall lens fit was evaluated by the Investigators for each eye whether it was acceptable (yes/no).

Time frame: Dispensing

Population: Analysis was conducted on all randomized subjects who wore at least one pair of study lenses.

ArmMeasureValue (NUMBER)
EADE/EALELens Fit Acceptance100 % of Eyes
1-DMLens Fit Acceptance100 % of Eyes
Primary

Monocular Visual Acuity

Monocular distance Snellen visual acuity (VA) scores were coverted to the algorithm of the minimal angle of resolution (LogMAR) scale based on the following formula: LogMAR = Log10 (VA/20) - a\*VAR, where Log10 = base 10 logarithm, VA = the Snellen denominator score, a = LogMAR stepsize coefficient and VAR = letter gained or missing in addition to the Snellen denominator score.

Time frame: Dispensing

Population: Analysis was conducted on all randomized subjects who wore at least one pair of study lenses.

ArmMeasureValue (MEAN)Dispersion
EADE/EALEMonocular Visual Acuity-0.044 LogMAR scoreStandard Deviation 0.0618
1-DMMonocular Visual Acuity-0.060 LogMAR scoreStandard Deviation 0.0589
Comparison: The alternative hypothesis is the monocular distance Snellen VA (LogMAR scale) of etafilcon A with embedded print and PVP for dark/light eyes is non-inferior to that of etafilcon A control lenses.95% CI: [0.004, 0.017]Mixed Models Analysis

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026